Zydus Cadila has received final approval from the US health regulator to market Memantine Hydrochloride tablets, used to treat dementia, in America, its listed entity Cadila Healthcare said today.
"Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Memantine Hydrochloride tablets USP, 5mg and 10mg," Cadila Healthcare said in a BSE filing.
The company will manufacture the drug at its plant in Moraiya, Ahmedabad.
It has more than 120 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
The stock was trading 0.07 per cent down at Rs 517.15 apiece on BSE today.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)